Compugen drug effective vs. type I diabetes animal model

• Compugen (NASDAQ:CGEN) +4.8% premarket after announcing a study of its CGEN-15001 Fc fusion protein drug candidate demonstrated high effectiveness in an animal model of autoimmune type I diabetes.
• The study suggests the drug turns off the autoimmune process and may potentially lead to restoration of immune tolerance and resolution of autoimmunity, arresting disease progression.